Assessment of activating estrogen receptor 1 (<i>ESR1</i>) mutations in gynecologic malignancies.

Gaillard, Stéphanie; Steiner, M.; Andreano, Kaitlyn J.; Davidson, Brittany; Havrilesky, Laura J.; Secord, Angeles Alvarez; Valea, Fidel A.; Colón‐Otero, Gerardo; Zajchowski, Deborah A.; Chang, Ching‐yi; McDonnell, Donald P.; Berchuck, Andrew; Elvin, Julia A.

doi:10.1200/jco.2018.36.15_suppl.5590

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This will be necessary to more effectively guide the use of endocrine therapy. In addition, mutations in ESR1 (the gene encoding ERalpha)conferring constitutive activity are emerging as resistance mechanisms to endocrine therapy in gynecologic malignancies, similar to the emergence of these mutations in endocrine resistant breast cancer [56].…”

Section: Molecular Alterations Identify Potential Targeted Therapiesmentioning

confidence: 99%

Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer

Yen

Wang

Fader

et al. 2020

International Journal of Gynecological Pathology

107

View full text Add to dashboard Cite

Recent advances in molecular studies, especially genome-wide analyses, have revealed the landscape of genomic alterations present in endometrial carcinomas, and have provided valuable insight into the pathogenesis of this disease. The current challenges are in developing a molecularmorphological classification system to enhance traditional pathologic diagnosis and in determining the optimal approach to using this new information to guide clinical management. Molecular assays may be particularly beneficial in allowing the earlier detection of endometrial cancer or precursor lesions and in guiding personalized treatment approaches. In this review, we describe the current molecular landscape of endometrial cancers, efforts underway to incorporate molecular alterations into the current classification systems, and the development of diagnostic tools for the early detection of endometrial cancer. Finally, we present opportunities for using these data to tailor therapeutic strategies. A comprehensive understanding of the molecular alterations responsible for the origination, relapse, and resistance patterns of this disease will ultimately improve outcomes for patients with endometrial cancer.

show abstract

Section: Molecular Alterations Identify Potential Targeted Therapiesmentioning

confidence: 99%